Severe Malaria, Pascalian Therapeutics, and the US Food and Drug Administration (FDA)

Issued Date

2022-07-15

Resource Type

Letter

ISSN

10584838

eISSN

15376591

DOI

10.1093/cid/ciac024

Scopus ID

2-s2.0-85137124619

Pubmed ID

35023549

Journal Title

Clinical Infectious Diseases

Volume

75

Issue

2

Rights Holder(s)

SCOPUS

Bibliographic Citation

Clinical Infectious Diseases Vol.75 No.2 (2022) , 358

Suggested Citation

White N.J., Watson J.A., Simpson J.A. Severe Malaria, Pascalian Therapeutics, and the US Food and Drug Administration (FDA). Clinical Infectious Diseases Vol.75 No.2 (2022) , 358. doi:10.1093/cid/ciac024 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85716

Title

Severe Malaria, Pascalian Therapeutics, and the US Food and Drug Administration (FDA)

Author(s)

White N.J.
 Watson J.A.
 Simpson J.A.

Author's Affiliation

Mahidol Oxford Tropical Medicine Research Unit
 Melbourne School of Population and Global Health

Other Contributor(s)

Mahidol University

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/85716

Collections

Scopus 2022